A clinical study on stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis
Journal Title: Journal of Cancer Research & Therapy - Year 2013, Vol 1, Issue 5
Abstract
Purposes: Hepatocellular carcinoma with portal vein tumor thrombosis (HCC-PVTT) has a poor prognosis, while the optimal treatment remains controversial. The objective of this retrospective study was to evaluate the efficacy and safety of γ- ray SBRT in treatment of patients with HCC-PVTT. Methods: The study was designed to examine the effects of γ- ray SBRT on toxicity and survival in patients with HCC-PVTT. To this end, data from patients with HCC-PVTT who received γ- ray SBRT during May 2008 to December 2011 was collected and analyzed. Response and (acute and late) toxicity were evaluated using the established international criteria. Log-rank test and Cox regression model were used to identify predictive factors and multivariate for survival, respectively. Results: The median follow up was 11 months. Fifty four consecutive patients with HCC-PVTT received daily fraction of 2.6 - 6Gy and six fractions per week for the total dose of 32.4 - 54Gy in 6 - 13 days. Six complete response (CR; 11.1%) and twenty five partial response (PR; 46.3%) were observed (overall response rate 57.4%). Twenty three patients displayed a stable disease (SD; 42.6%), while no patient experienced progressive disease (PD; 0%). The treatment was well tolerated with no radiation-related complication and no ≤ Grade 3 toxicity. One- and two-year overall survival rate were 33.4% and 13.6% respectively, and median overall survival was 10.7 months. The prognostic factors for survival included ECOG performance status (P=0.04), Child-Pugh score (P=0.05), PVTT size (P=0.02) and location (P=0.05). Conclusions: Individual γ - ray SBRT appears to be feasible for treatment of patients with HCC-PVTT in whom other current therapies are contraindicated. PVTT size and ECOG performance status may represent the strongest predictive factors for survival.
Authors and Affiliations
Zhong NB, Chen ZH, LV GM
Keywords
Related Articles
- EP ID EP551296
- DOI 10.14312/2052-4994.2013-22
- Views 73
- Downloads 0
Antioxidant activity of some benzimidazole derivatives to definite tumor cell lines
A group of bis(benzimidazol-2-yl) amines have been already evaluated for cytotoxicity in vitro to human colorectal cancer cell line HT-29, breast cancer cells MDA-MB-231 and normal spleen cells and two of them (B1 and B2...
Combination chemotherapy of cancer using the inhibitor of DNA methylation 5-aza-2'-deoxycytidine (decitabine)
The epigenetic alterations marked by DNA methylation contribute to the malignant transformation of cells by silencing critical genes responsible for the regulation of growth. The potent DNA methylation inhibitor 5-aza-2’...
A clinical study on stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis
Purposes: Hepatocellular carcinoma with portal vein tumor thrombosis (HCC-PVTT) has a poor prognosis, while the optimal treatment remains controversial. The objective of this retrospective study was to evaluate the effic...
Small satellite pulmonary nodules in operable lung cancer: Diagnosis and therapeutic strategy
Objective: The use of high-resolution computed tomography (HRCT) has improved the management of non-small cell lung cancer (NSCLC), but has also increased the detection of indeterminate satellite nodules. Obtaining diffe...
Split-course chemoradiotherapy with S-1, a novel oral fluorouracil, and cisplatin for distant metastases of oesophageal cancer stage IVb
Objectives: To evaluate the efficacy and safety of split-course chemoradiotherapy with S-1, a novel oral fluorouracil, together with cisplatin in patients with distant oesophageal cancer stage IVb metastasis. Methods: Fo...